Liaoning Chengda Biotechnology Co Ltd
SSE:688739
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.14
34.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Liaoning Chengda Biotechnology Co Ltd
Liaoning Chengda Biotechnology Co Ltd
Operating Income
Liaoning Chengda Biotechnology Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
|
Operating Income
¥522.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Income
-¥8.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Income
¥1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Operating Income
¥2.3B
|
CAGR 3-Years
31%
|
CAGR 5-Years
46%
|
CAGR 10-Years
23%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Income
¥7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
50%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Operating Income
¥2.1B
|
CAGR 3-Years
64%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
Liaoning Chengda Biotechnology Co Ltd
Glance View
Liaoning Chengda Biotechnology Co., Ltd. is engaged in the research, development, manufacture and sale of vaccines. The company is headquartered in Shenyang, Liaoning and currently employs 1,663 full-time employees. The company went IPO on 2021-10-28. The firm's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The firm's products include two brands: Chengda Suda and Chengda Libao.
See Also
What is Liaoning Chengda Biotechnology Co Ltd's Operating Income?
Operating Income
522.7m
CNY
Based on the financial report for Dec 31, 2023, Liaoning Chengda Biotechnology Co Ltd's Operating Income amounts to 522.7m CNY.
What is Liaoning Chengda Biotechnology Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-5%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for Liaoning Chengda Biotechnology Co Ltd have been -19% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
